Glucuronides in Anti-Cancer Therapy

Author(s): Xi Chen , Bingyuan Wu , Peng George Wang .

Journal Name: Current Medicinal Chemistry - Anti-Cancer Agents

Volume 3 , Issue 2 , 2003

Abstract:

Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor β-glucuronidase activity. β-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT), and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.

Keywords: glucuronides, anti cancer therapy, glucuronide prodrug, prodrug monotherapy, antibody directed enzyme prodrug therapy, combined chemo radiotherapy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 2
Year: 2003
Page: [139 - 150]
Pages: 12
DOI: 10.2174/1568011033353470
Price: $58

Article Metrics

PDF: 7